

Double Diabetes: Introduction, Overview, and Literature Review

Salih H. S. Hamid ^a, Alaa Ali Elsharief Hammad ^a, Hassan I. Osman ^b

^a salihhamidsd@gmail.com

a = Endocrinology Unit, Department of Internal Medicine, Soba University Hospital, Khartoum, Khartoum, Sudan

b = Napata Research and Innovation Center (NRIC), Napata College, Khartoum North, Khartoum, Sudan

Abstract

In this paper, we address double diabetes, a phenomenon infrequently discussed amongst experts.

It is said to come to be when individuals suffering from type I diabetes manifest with signs and symptoms suggestive of type II diabetes.

Double Diabetes (DD) is a peculiar phenomenon that has manifested itself as a possible occurrence in those suffering from type I diabetes. Despite the necessity for more studies that elaborate on how double diabetes comes to be, it seems as if increased BMI and increased insulin doses may be hypothesized as a goal. Other hypotheses, such as the immunological deficiency playing a role require more studies.

Keywords: Double Diabetes; Endocrinology; DD

Introduction:

The World Health Organization characterizes diabetes as a group of illnesses of a metabolic nature that are characterized by hyperglycemia and its adverse effects (1,2). It is agreed upon that, in general, two types of DM exist. Those being: Type 1 and Type 2 diabetes and are differentiated via clinical criteria (3). However, as it stands, double diabetes is only identified as occurring in individuals who manifest both types of diabetes. It is of the utmost importance that we study the natural course of development of double diabetes so as to evolve preventative methods (4).

Risk Factors:

Published data is insufficient to accurately state the prevalence of metabolic syndrome (MS) amongst the general population. However, it probably occurs at a 25% rate worldwide (2,5)

A study published in 2015 reported that a staggering 70 countries experienced doubling of obesity prevalence between 1980 and 2015 (6).

Type 1 Diabetes:

Individuals living with type 1 diabetes usually suffer from excess bodily weight and are either overweight or gain weight more rapidly than those who do not suffer from the illness (6,7).

Type 2 Diabetes:

This is a rather common condition that comes to be through gradual failure of pancreatic β -cells as well as insulin resistance (8,9).

Double Diabetes:

At first, the classification of diabetes seems rather straightforward. However, there exist cases (probably as much as 25% of all cases) (10,11) in which features diagnostic of both types manifest in a patient suffering from type 1 diabetes. In such cases, the patient is said to suffer from double diabetes (10,12–14). This was first elaborated to back in 1991 by Teupe and Bergis (15). Double Diabetes occurs seems to occur in individuals suffering from type 1 diabetes, especially those who are overweight (16–19). Despite this

indicating that double diabetes may be a progression of type 1 diabetes, it seems more likely that more pathophysiological phenomena are at play (10,20).

A case reported in 2003 (21) illustrated that Double Diabetes could present in individuals as young as 5 years of age.

Double diabetes can be diagnosed when, in addition to diagnostic features of Type 1 diabetes, family history of type 2 diabetes, hypertension, weight gain while receiving insulin, features of insulin resistance, and low HDL count are observed (22).

Epidemiology:

Prevalence of double diabetes can be estimated to be as high as 30% in individuals suffering from type 1 diabetes (9,16)

Pathophysiology:

Despite the discussion still ongoing (20), it is not implausible to hypothesize that insulin treatment, through its mechanism of action that could possibly result in weight gain, may itself play a role in the development of double diabetes (23).

The insulin resistance hypothesis (The accelerator hypothesis) is, by no means new, it was discussed as a possibility for the association between type I and type II diabetes back in 2009 (24).

The possibility of the established impaired immunity (decreased IgG concentrations) in individuals living with type I diabetes may play a role in the manifestation of double diabetes; however not enough such studies have been conducted (10,25–28).

It also seems plausible to hypothesize that double diabetes may result in adverse atherothrombotic manifestations (29).

Conclusion:

In conclusion, Double Diabetes (DD) is a peculiar phenomenon that has manifested itself as a possible occurrence in those suffering from type I diabetes. Despite the necessity for more studies that elaborate on how double diabetes comes to be, it seems as if increased BMI and increased insulin doses may be hypothesized as a goal. Other hypotheses, such as the immunological deficiency playing a role require more studies.

References:

1. Classification of diabetes mellitus. Geneva: World Health Organization [Internet]. WHO. Geneva; 2019. Available from: <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>.
2. Bielka W, Przekaz A, Molęda P, Pius-Sadowska E, Machaliński B. Double diabetes—when type 1 diabetes meets type 2 diabetes: definition, pathogenesis and recognition. *Cardiovasc Diabetol* [Internet]. 2024;23(1):1–13. Available from: <https://doi.org/10.1186/s12933-024-02145-x>
3. Leslie R, Palmer J, Schloot N, Lernmark A. Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment. *Diabetologia*. 2016;59(1):13–20.
4. Gale E. The rise of childhood type 1 diabetes in the 20th century. *Diabetes*. 2002;51(12):3353–61.
5. Saklayen M. The global epidemic of the metabolic syndrome. *Curr Hypertens Rep*. 2018;20(2):12.
6. Afshin A, Forouzanfar M, Reitsma M, Sur P, Estep K, Lee A, et al. Health effects of overweight and obesity in 195 countries over 25 years. *N Engl J Med*. 2017;377(1):13–27.
7. Szadkowska A, Madej A, Ziółkowska K, Szymańska M, Jeziorny K, Mianowska B, et al. Gender and age—dependent effect of type 1 diabetes on obesity and altered body composition in young adults. *Ann Agric Environ Med*. 2015;22(1):124–8.
8. Leahy J. Pathogenesis of type 2 diabetes mellitus. *Arch Med Res*. 2005;36:197–209.
9. Kietsiroje N, Pearson S, Campbell M, Ariëns RAS, Ajjan RA. Double diabetes: A distinct high-risk group?

Diabetes Obes Metab. 2019;21(12):2609–18.

10. Khawandanah J. Double or hybrid diabetes: A systematic review on disease prevalence, characteristics and risk factors. *Nutr Diabetes* [Internet]. 2019;9(1):1–9. Available from: <http://dx.doi.org/10.1038/s41387-019-0101-1>
11. Scott CR, et al. Characteristics of youth-onset non-insulin-dependent diabetes mellitus and insulin-dependent diabetes mellitus at diagnosis. *Pediatrics*. 1997;100:84–91.
12. Teupe B, Bergis K. Epidemiological evidence for ‘double diabetes.’ *Lancet*. 1991;337(8737):361–2.
13. Libman I, Becker D. Coexistence of type 1 and type 2 diabetes mellitus: ‘double’ diabetes? *Pediatr Diabetes*. 2003;4(2):110–3.
14. Merger S, Kerner W, Stadler M, Zeyfang A, Jehle P, Müller-Korbsch M, et al. Prevalence and comorbidities of double diabetes. *Diabetes Res Clin Pract*. 2016;1(119):48–56.
15. Teupe B, Bergis K. Epidemiological evidence for “double diabetes.” *Lancet*. 1991;337:361–2.
16. Conway B, Miller R, Costacou T, Al. E. Temporal patterns in over- weight and obesity in type 1 diabetes. *Diabet Med*. 2010;27:398–404.
17. De Keukelaere M, Fieuws S, Reynaert N, Al. E. Evolution of body mass index in children with type 1 diabetes mellitus. *Eur J Pediatr*. 2018;177:1661–6.
18. Pozzilli P, Guglielmi C, Caprio S, Buzzetti R. Obesity, autoimmunity, and double diabetes in youth. *Diabetes Care*. 2011;34:166–70.
19. Purnell J, Hokanson J, Marcovina S, Steffes M, Cleary P, Brunzell J. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. *Diabetes Control and Complications Trial*. *JAMA*. 1998;280(2):140–6.
20. Giuffrida FMA, Bulcão C, Cobas RA, Negrato CA, Gomes MB, Dib SA. Double-diabetes in a real-world sample of 2711 individuals: Associated with insulin treatment or part of the heterogeneity of type 1 diabetes? *Diabetol Metab Syndr*. 2016;8(1):1–10.
21. Libman I, Becker D. Coexistence of type 1 and type 2 diabetes mellitus: “double” diabetes? *Pediatr Diabetes*. 2003;4:110–3.
22. Cleland S. Cardiovascular risk in double diabetes mellitus—when two worlds collide. *Nat Rev Endocrinol*. 2012;8:476–85.
23. Giuffrida F, Guedes A, ER R, DB M, P D, OS M, et al. Brazilian Type 1 Diabetes Study Group (BrazDiab1SG). Heterogeneous behavior of lipids according to HbA1c levels undermines the plausibility of metabolic syndrome in type 1 diabetes: data from a nationwide multicenter survey. *Cardiovasc Diabetol*. 2012;11:156.
24. Wilkin TJ. The accelerator hypothesis: A review of the evidence for insulin resistance as the basis for type I as well as type II diabetes. *Int J Obes* [Internet]. 2009;33(7):716–26. Available from: <http://dx.doi.org/10.1038/ijo.2009.97>
25. Guo X, et al. Serum levels of immunoglobulins in an adult population and their relationship with type 2 diabetes. *Diabetes Res Clin Pr*. 2016;115:76–82.
26. Hoddinott S, Al. E. Immunoglobulin Levels, Immunodeficiency and HLA in Type 1 (Insulin-Dependent) Diabetes Mellitus. *Diabetologia*. 1982;23:326–329.
27. Wang Z, Al. E. Immunoglobulin E and mast cell proteases are potential risk factors of human pre-diabetes and diabetes mellitus. *PLoS One*. 2011;6:28962.
28. Mazer NA, Al. E. Immunoglobulin deficiency in patients with diabetes mellitus. *J Allergy Clin Immunol*. 2011;127:AB12–AB12.
29. Cleland SJ. Cardiovascular risk in double diabetes mellitus when two worlds collide. *Nat Rev Endocrinol*. 2012;8:476–485.